at 2153 has been researched along with Carcinoma, Ehrlich Tumor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, J; Ye, QX; Zhang, TM; Zhang, Y; Zhang, ZY | 1 |
| Li, GD; Liu, TX; Wang, MY; Zhang, TM | 1 |
2 other study(ies) available for at 2153 and Carcinoma, Ehrlich Tumor
| Article | Year |
|---|---|
Synergistic effect of probimane on anticancer cytotoxicity of doxorubicin in vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Ehrlich Tumor; Doxorubicin; Drug Synergism; Male; Malondialdehyde; Mice; Mitochondria; Neoplasm Transplantation; Razoxane; Tumor Cells, Cultured | 1994 |
[Effects of bimolane and probimane on the incorporation of (3H)TdR, (3H)UR and (3H)Leu into Ehrlich ascites carcinoma cells iv vitro].
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; DNA, Neoplasm; Female; Leucine; Male; Mice; Piperazines; Razoxane; RNA, Neoplasm; Thymidine; Tumor Cells, Cultured; Uridine | 1988 |